Sanjay R Mehta1,2, Cynthia Schairer3, Susan Little4. 1. Departments of Medicine and Pathology, University of California San Diego. 2. Department of Medicine San Diego Veterans Affairs Medical Center. 3. Department of Psychiatry, University of California San Diego. 4. Department of Medicine, University of California San Diego, San Diego, California, USA.
Abstract
PURPOSE OF REVIEW: HIV phylogenetic and molecular epidemiology analyses are increasingly being performed with a goal of improving HIV prevention efforts. However, ethical, legal and social issues are associated with these analyses, and should be considered when performed. RECENT FINDINGS: Several working groups have recently outlined the major issues surrounding the use of molecular epidemiology for HIV prevention. First, the benefits of HIV molecular epidemiology remain unclear, and further work is needed to quantitatively demonstrate the benefits that can be expected. Second, privacy loss is an important risk, with implications of disclosure varying by the regional legal and social climate. Inferential privacy risks will increase with technological improvements in sequencing and analysis. Third, data sharing, which enhances the utility of the data, may also increase the risk of inferential privacy loss. Mitigation strategies are available to address each of these issues. SUMMARY: HIV molecular epidemiology for research and public health pose significant ethical issues that continue to evolve with improving technology, increased sampling and a changing legal and social climate. Guidance surrounding these issues needs to be developed for researchers and public health officials in an iterative and region specific manner that accounts for the potential benefits and risks of this technology.
PURPOSE OF REVIEW: HIV phylogenetic and molecular epidemiology analyses are increasingly being performed with a goal of improving HIV prevention efforts. However, ethical, legal and social issues are associated with these analyses, and should be considered when performed. RECENT FINDINGS: Several working groups have recently outlined the major issues surrounding the use of molecular epidemiology for HIV prevention. First, the benefits of HIV molecular epidemiology remain unclear, and further work is needed to quantitatively demonstrate the benefits that can be expected. Second, privacy loss is an important risk, with implications of disclosure varying by the regional legal and social climate. Inferential privacy risks will increase with technological improvements in sequencing and analysis. Third, data sharing, which enhances the utility of the data, may also increase the risk of inferential privacy loss. Mitigation strategies are available to address each of these issues. SUMMARY: HIV molecular epidemiology for research and public health pose significant ethical issues that continue to evolve with improving technology, increased sampling and a changing legal and social climate. Guidance surrounding these issues needs to be developed for researchers and public health officials in an iterative and region specific manner that accounts for the potential benefits and risks of this technology.
Authors: Albert Liu; David V Glidden; Peter L Anderson; K Rivet Amico; Vanessa McMahan; Megha Mehrotra; Javier R Lama; John MacRae; Juan Carlos Hinojosa; Orlando Montoya; Valdilea G Veloso; Mauro Schechter; Esper G Kallas; Suwat Chariyalerstak; Linda-Gail Bekker; Kenneth Mayer; Susan Buchbinder; Robert Grant Journal: J Acquir Immune Defic Syndr Date: 2014-12-15 Impact factor: 3.731
Authors: Sanjay R Mehta; Antoine Chaillon; Tommi L Gaines; Patricia E Gonzalez-Zuniga; Jamila K Stockman; Horatio Almanza-Reyes; Jose Roman Chavez; Alicia Vera; Karla D Wagner; Thomas L Patterson; Brianna Scott; Davey M Smith; Steffanie A Strathdee Journal: Clin Infect Dis Date: 2018-02-10 Impact factor: 9.079
Authors: M Thomas P Gilbert; Andrew Rambaut; Gabriela Wlasiuk; Thomas J Spira; Arthur E Pitchenik; Michael Worobey Journal: Proc Natl Acad Sci U S A Date: 2007-10-31 Impact factor: 11.205
Authors: James I Brooks; Harrison Niznick; Marianna Ofner; Harriet Merks; Jonathan B Angel Journal: BMC Infect Dis Date: 2013-10-30 Impact factor: 3.090
Authors: Susan J Little; Sergei L Kosakovsky Pond; Christy M Anderson; Jason A Young; Joel O Wertheim; Sanjay R Mehta; Susanne May; Davey M Smith Journal: PLoS One Date: 2014-06-05 Impact factor: 3.240
Authors: Joel O Wertheim; Andrew J Leigh Brown; N Lance Hepler; Sanjay R Mehta; Douglas D Richman; Davey M Smith; Sergei L Kosakovsky Pond Journal: J Infect Dis Date: 2013-10-22 Impact factor: 5.226
Authors: Alic G Shook; Susan E Buskin; Matthew Golden; Julia C Dombrowski; Joshua Herbeck; Richard J Lechtenberg; Roxanne Kerani Journal: J Assoc Nurses AIDS Care Date: 2021-10-26 Impact factor: 1.809
Authors: Jon A Steingrimsson; John Fulton; Mark Howison; Vlad Novitsky; Fizza S Gillani; Thomas Bertrand; Anna Civitarese; Katharine Howe; Guillermo Ronquillo; Benjamin Lafazia; Zoanne Parillo; Theodore Marak; Philip A Chan; Lila Bhattarai; Casey Dunn; Utpala Bandy; Nicole Alexander Scott; Joseph W Hogan; Rami Kantor Journal: BMJ Open Date: 2022-04-21 Impact factor: 3.006